Selective CD28 Blockade in Renal Transplant Recipients
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and efficacy of lulizumab, a CD28-specific
domain antibody (CD28 dAb), compared to tacrolimus, as the primary immunosuppressant in
first-time renal transplant recipients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)